SCHEMBL4488013

SCHEMBL4488013

Cc1[nH]c(C)c(-c2ccc(-c3ccccc3Cl)nc2)c(=O)c1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.45
BRD4 O60885 1/20 0.39
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
DHODH Q02127 2/20 0.36
TNKS2 Q9H2K2 1/20 0.36
PIM1 P11309 1/20 0.35
MET P08581 1/20 0.35
IDO1 P14902 1/20 0.35
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473576 0.88 LMNA (0.40) SLC2A1BRD4LMNAGAATSHR
SCHEMBL4486512 0.86 SLC2A1 (0.47) SLC2A1DHODHTNKS2IDO1MAPKAPK2
SCHEMBL4490477 0.84 SLC2A1 (0.48) SLC2A1BRD4POLBKMT2ADHODH
SCHEMBL4489336 0.83 SLC2A1 (0.52) SLC2A1MAPKAPK2HSD11B1
SCHEMBL4487868 0.83 SLC2A1 (0.45) SLC2A1BRD4GAAKMT2AGRIN2D
SCHEMBL4484308 0.80 SLC2A1 (0.48) SLC2A1LMNAGAAHTTKMT2A
SCHEMBL4464652 0.78 SLC2A1 (0.47) SLC2A1PIM1MET
SCHEMBL4490980 0.76 SCD (0.45) SLC2A1DHODHTNKS2IDO1MAPKAPK2
SCHEMBL4487292 0.76 SLC2A1 (0.44) SLC2A1SCD
SCHEMBL4479169 0.75 SLC2A1 (0.43) SLC2A1GAAHTTGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP claimed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885BRD4 2655/4885LMNA 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.